MOTS-c is a mitochondrial-derived peptide studied in metabolism. Foundational experiments investigated cellular pathways and reported metabolic effects in mice. That research supports investigation of a biological hypothesis; it does not establish that a spray produces clinical benefits in people. Original MOTS c metabolic experiments

Keep endogenous measurement separate from treatment

A study that measures a naturally occurring peptide in humans asks a different question from a study that administers a manufactured preparation. An association with exercise or metabolic health does not prove that giving the peptide reproduces those effects. Material identity and route add further questions.

For a spray claim, researchers would need to show that the particular formulation delivers a relevant exposure and then evaluate meaningful outcomes and safety. Animal evidence from another route cannot answer those questions by substitution. A convenient delivery format does not shorten the evidentiary steps.

Scientific uncertainty survives a policy change

FDA's 2026 MOTS-c scientific assessment addresses evidence and quality questions relevant to compounding review. The October 30, 2026 Federal Register notice describes a draft, nonbinding HHS policy for conditional enforcement discretion under section 503A. It also describes interim application while the bulks list is developed, so draft status should not be mistaken for an absence of interim enforcement effect. Whether a particular preparation falls within the policy depends on its conditions and scope. This is not FDA approval or evidence that a MOTS-c spray is safe or effective. FDA MOTS c compounding scientific assessment Federal Register peptide policy notice October 30 2026 HHS peptide compounding enforcement discretion policy

An accurate AXON article should distinguish the native molecule, the preparation used in an experiment and an offered product. It should also separate preclinical findings from controlled human intervention evidence.

The defensible conclusion is that metabolic interest in MOTS-c does not validate a spray formulation. This draft makes no efficacy claim for human use and provides no preparation, administration or dosing instructions. A metabolic researcher and regulatory specialist should review any product-specific statement, including whether the exact form and route fall within a current policy.